ICON PLC - Asset Resilience Ratio
ICON PLC (ICLR) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ICON PLC (ICLR) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2024)
This chart shows how ICON PLC's Asset Resilience Ratio has changed over time. See ICLR book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ICON PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ICON PLC stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ICON PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ICON PLC Industry Peers by Asset Resilience Ratio
Compare ICON PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for ICON PLC (1998–2024)
The table below shows the annual Asset Resilience Ratio data for ICON PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $16.88 Billion | -- |
| 2023-12-31 | 0.01% | $1.95 Million | $16.99 Billion | +0.00pp |
| 2022-12-31 | 0.01% | $1.71 Million | $17.19 Billion | +0.00pp |
| 2021-12-31 | 0.01% | $1.71 Million | $17.39 Billion | -0.04pp |
| 2020-12-31 | 0.05% | $1.73 Million | $3.44 Billion | -1.66pp |
| 2019-12-31 | 1.71% | $49.63 Million | $2.91 Billion | -0.80pp |
| 2018-12-31 | 2.51% | $59.91 Million | $2.39 Billion | -1.04pp |
| 2017-12-31 | 3.55% | $77.59 Million | $2.19 Billion | -0.18pp |
| 2016-12-31 | 3.73% | $68.05 Million | $1.83 Billion | -1.28pp |
| 2015-12-31 | 5.00% | $85.99 Million | $1.72 Billion | -1.35pp |
| 2014-12-31 | 6.36% | $97.10 Million | $1.53 Billion | -3.23pp |
| 2013-12-31 | 9.59% | $138.32 Million | $1.44 Billion | +3.25pp |
| 2012-12-31 | 6.34% | $76.18 Million | $1.20 Billion | +1.03pp |
| 2011-12-31 | 5.31% | $54.94 Million | $1.04 Billion | -0.11pp |
| 2009-12-31 | 5.42% | $49.23 Million | $908.40 Million | +0.49pp |
| 2008-12-31 | 4.93% | $42.73 Million | $867.28 Million | -1.10pp |
| 2007-12-31 | 6.02% | $41.75 Million | $693.14 Million | -2.34pp |
| 2006-12-31 | 8.36% | $39.82 Million | $476.34 Million | +1.83pp |
| 2005-12-31 | 6.53% | $22.81 Million | $349.07 Million | -0.35pp |
| 2004-12-31 | 6.88% | $23.09 Million | $335.32 Million | +1.07pp |
| 2003-12-31 | 5.82% | $10.88 Million | $186.92 Million | -6.67pp |
| 2001-12-31 | 12.49% | $18.52 Million | $148.32 Million | -18.47pp |
| 2000-12-31 | 30.96% | $34.32 Million | $110.87 Million | +9.58pp |
| 1999-12-31 | 21.38% | $21.41 Million | $100.12 Million | -16.89pp |
| 1998-12-31 | 38.27% | $35.90 Million | $93.80 Million | -- |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more